6533b82afe1ef96bd128b963
RESEARCH PRODUCT
Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.
Pedro González-santosMariano BlascoJesús MillánÁNgel DíazTeresa MantillaJuan F. AscasoAntonio Hernández-mijaresJuan Pedro-botetÁNgel BreaXavier Pintósubject
medicine.medical_specialtyCirrhosisDiseaseGastroenterologyLiver diseaseNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansGeneral Environmental Sciencebusiness.industryGeneral EngineeringArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary SciencesSteatosisSteatohepatitisLiver cancerbusinessdescription
Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influence on cardiovascular disease and drugs used in the control of cardiovascular risk factors showing a beneficial effect on the liver disease will be reviewed.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-06-24 | Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis |